Replies to post #18364 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 1Q19 sales by business segment:

 
 Medical devices* 38% (+10% YoY in const currency)   
 Diagnostics      24% ( +4% YoY in const currency)   
 Nutrition        24% ( +7% YoY in const currency)  
 Drugs†           13% ( +5% YoY in const currency)

63% of overall sales were ex-US.

*Including diabetes care.
†Branded generics in emerging markets.

[DewDiligence]

ABT raises 2019 EPS guidance based on 2Q19 results—new range for non-GAAP EPS is $3.21-3.27 (up from the prior range of $3.15-3.25), which equates to 13% YoY growth at the midpoint of the range.

(2019 GAAP EPS guidance was raised to $2.06-2.12, up from the prior range of $1.95-2.05.)

2Q19 Freestyle Libre sales were $433M, +73% YoY in constant currency. Freestyle Libre has bona fide blockbuster potential (#msg-149945255).

--
2Q19 PR:
https://www.abbottinvestor.com/static-files/12f8c8d7-de07-4b51-98c3-1290c91dab25

2Q19 infographic:
https://www.abbottinvestor.com/static-files/20151f0a-d75c-4a99-a4fd-eb76ebf94020